Mein Warenkorb

IgG

IgG Molekülinformation

Englischer NameImmunoglobulin GAnzahl der inverkehr gebrachten Arzneimittel1
Anzahl der klinischen Arzneimittel8Target-AliasImmunoglobulin G
Höchste Forschungs- und EntwicklungsphaseApproved
Englischer NameImmunoglobulin G
Target-AliasImmunoglobulin G
Anzahl der inverkehr gebrachten Arzneimittel1
Anzahl der klinischen Arzneimittel8
Höchste Forschungs- und EntwicklungsphaseApproved

IgG Produktliste

  • Attribut

    Antibody (6)

  • Produktbibliothek

    Online (6)

  • Spezies

    Mouse (6)

  • Etikett

    - (6)

  • Marker

    HRP Labeled (1)Acridinium ester Labeled (1)Biotin-labeled (1)PE Labeled (1)Europium chelate Labeled (1)FA Labeled (1)

IgG Molekülhintergrund

The Anti-Human IgG-Acridine Ester is an acridinium ester labeled Monoclonal mouse anti-human IgG antibody can be used to capture the human IgG in Chemiluminescence procedures. The antibody reacts with the Fc portion of human IgG heavy chain but not with the Fab portion of human IgG. No antibody was detected against human IgM or IgA, or against non-immunoglobulin serum proteins. The antibody has been tested by ELISA and/or solid-phase adsorbed to ensure minimal cross-reaction with mouse, cynomolgus and bovine serum proteins, but it is not sure if the product cross-react with immunoglobulins from other species. Acridinium ester is one of the most commonly used excited substrates for protein labeling and widely used in automated instruments because of its high sensitivity with detection limits in the attomole range. Acridinium ester can be triggering by chemiluminescent substrate solution and generate intense signal, the result signals (relative light units, RLU) can be measured at 430 nm. The Anti-human IgG-Acridine Ester is easy to capture the human IgG, and the bounded human IgG have no activity lost, this ready to use products could greatly save your protein labeling time and hassle, and help us get the best performance and highly reproducible results.

IgG Molekülalias

IgG

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
RicefidaseKJ-103; KJ103Phase 3 ClinicalShanghai Bao Pharmaceuticals Co LtdAnti-Glomerular Basement Membrane Disease; Guillain-Barre Syndrome; Rejection of renal transplantation
Details
AT-02AT-02Phase 2 ClinicalAttralus IncAmyloidosis; Immunoglobulin Light-chain Amyloidosis
Details
JZB-34AAFP; JZB-34Phase 1 ClinicalShanghai Kexin Biotech Co LtdHypersensitivity
Details
Emicizumab biosimilar (Jushi Biopharmaceutical)SYS6053; SYS-6053Phase 1 ClinicalJushi Biopharmaceutical Co LtdHemophilia A; Hemorrhage
Details
S-1117S-1117Phase 1 ClinicalSeismic Therapeutics IncImmune System Diseases
Details
BHV-1300BHV-1300Phase 1 ClinicalBiohaven Pharmaceuticals IncArthritis, Rheumatoid; Graves Disease
Details
HNSA-5487HNSA 5487; HNSA-5487Phase 1 ClinicalHansa Biopharma AbAutoimmune Diseases; Neoplasms
Details
Anti-CD33/anti-FcgammaRI bispecific antibody (UCSD)Phase 1 ClinicalUniversity Of California San DiegoLeukemia, Myeloid, Acute
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
ImlifidaseMac-1ApprovedHansamed IncIdefirixEURejection of renal transplantationHansa Biopharma Ab2020-08-25Guillain-Barre Syndrome; Kidney Diseases; Kidney Failure, Chronic; Purpura, Thrombotic Thrombocytopenic; Rejection of renal transplantation; Rejection of organ transplantation; Renal Insufficiency, Chronic
Details
  • Molekülinformation
  • Produktliste
  • Inverkehr gebrachte Arzneimittelinformation
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns